JP2018524575A - 疾患の診断におけるシトルリン化の役割 - Google Patents

疾患の診断におけるシトルリン化の役割 Download PDF

Info

Publication number
JP2018524575A
JP2018524575A JP2017565057A JP2017565057A JP2018524575A JP 2018524575 A JP2018524575 A JP 2018524575A JP 2017565057 A JP2017565057 A JP 2017565057A JP 2017565057 A JP2017565057 A JP 2017565057A JP 2018524575 A JP2018524575 A JP 2018524575A
Authority
JP
Japan
Prior art keywords
seq
citrullinated
disease
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017565057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524575A5 (enExample
Inventor
アイク ジェニファー ヴァン
アイク ジェニファー ヴァン
ジャスティナ フェルト‐ボベル
ジャスティナ フェルト‐ボベル
エリン クロウギー
エリン クロウギー
ロナルド ホールウィンスキ
ロナルド ホールウィンスキ
ベンジャミン フィリップ バーマン
ベンジャミン フィリップ バーマン
Original Assignee
シーダーズ−サイナイ メディカル センター
シーダーズ−サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ−サイナイ メディカル センター, シーダーズ−サイナイ メディカル センター filed Critical シーダーズ−サイナイ メディカル センター
Publication of JP2018524575A publication Critical patent/JP2018524575A/ja
Publication of JP2018524575A5 publication Critical patent/JP2018524575A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017565057A 2015-06-18 2016-06-20 疾患の診断におけるシトルリン化の役割 Pending JP2018524575A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562181665P 2015-06-18 2015-06-18
US62/181,665 2015-06-18
US201562233231P 2015-09-25 2015-09-25
US62/233,231 2015-09-25
US201562387149P 2015-12-23 2015-12-23
US62/387,149 2015-12-23
PCT/US2016/038439 WO2016205828A2 (en) 2015-06-18 2016-06-20 Role of citrullination in diagnosing diseases

Publications (2)

Publication Number Publication Date
JP2018524575A true JP2018524575A (ja) 2018-08-30
JP2018524575A5 JP2018524575A5 (enExample) 2019-07-25

Family

ID=57546510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565057A Pending JP2018524575A (ja) 2015-06-18 2016-06-20 疾患の診断におけるシトルリン化の役割

Country Status (5)

Country Link
US (1) US11105817B2 (enExample)
EP (1) EP3311176A4 (enExample)
JP (1) JP2018524575A (enExample)
CN (1) CN107923917A (enExample)
WO (1) WO2016205828A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
WO2021054375A1 (ja) * 2019-09-17 2021-03-25 キッコーマン株式会社 シトルリンの定量方法、定量用のオキシドレダクターゼ、定量用組成物、定量用キット、及びペプチジルアルギニンデイミナーゼの活性評価方法
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503610A (ja) 2017-11-16 2021-02-12 ブレインボックス ソルーションズ、インコーポレイテッドＢｒａｉｎｂｏｘ Ｓｏｌｕｔｉｏｎｓ， Ｉｎｃ． 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法
CN114839364B (zh) * 2022-04-27 2025-09-12 珠海丽珠试剂股份有限公司 抗突变型瓜氨酸化波形蛋白抗体检测试剂盒及其应用
EP4609859A1 (en) * 2024-02-28 2025-09-03 Universidad Pablo de Olavide Inhibitors of the gene smpd1 for the treatment of spinal muscular atrophy
CN118001407B (zh) * 2024-04-02 2024-06-21 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155226A (ja) * 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
JP2015021739A (ja) * 2013-07-16 2015-02-02 国立大学法人 熊本大学 質量分析におけるペプチドピークの同定・定量のためのデータベース作成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047518A1 (en) 1999-12-23 2001-07-05 Childrens Hospital Los Angeles Research Institute Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
SI1721162T1 (sl) 2004-02-27 2009-02-28 Roche Diagnostics Gmbh Postopek za ugotavljanje revmatoidnega artritisa z merjenjem anti-CCP in serumskega amiloida A
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
GB0803107D0 (en) 2008-02-20 2008-03-26 Axis Shield Diagnostics Ltd Method
WO2010048388A1 (en) 2008-10-22 2010-04-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunoassays for citrullinated proteins
AU2010224175A1 (en) 2009-03-10 2011-09-29 Duke University Predicting coronary artery disease and risk of cardiovascular events
IL225538A0 (en) 2009-03-30 2013-06-27 Nestec Sa Methods for the identification of anti-immune reaction peptides of anti-citrullinates
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US20140308676A1 (en) * 2010-11-12 2014-10-16 Justyna P. Fert-Bober Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
GB201213012D0 (en) * 2012-07-23 2012-09-05 Univ Warwick Diagnostic for determining skelektal health
WO2014037911A1 (en) * 2012-09-10 2014-03-13 Koninklijke Philips N.V. System and method for estimating susceptibility to a medical condition
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155226A (ja) * 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
JP2015021739A (ja) * 2013-07-16 2015-02-02 国立大学法人 熊本大学 質量分析におけるペプチドピークの同定・定量のためのデータベース作成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIN, Z. ET AL.: "Identification and characterization of citrulline-modified brain proteins by combining HCD and CID f", PROTEOMICS, vol. 13(17), JPN6020012725, 2013, pages 2682 - 2691, ISSN: 0004378835 *
石神 昭人: "老年医学の展望 シトルリン化分子と老年病", 日本老年医学会雑誌, vol. 51(4), JPN7020000995, July 2014 (2014-07-01), pages 314 - 320, ISSN: 0004245886 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases
WO2021054375A1 (ja) * 2019-09-17 2021-03-25 キッコーマン株式会社 シトルリンの定量方法、定量用のオキシドレダクターゼ、定量用組成物、定量用キット、及びペプチジルアルギニンデイミナーゼの活性評価方法
JPWO2021054375A1 (enExample) * 2019-09-17 2021-03-25
JP7737900B2 (ja) 2019-09-17 2025-09-11 キッコーマン株式会社 シトルリンの定量方法、定量用組成物、定量用キット、センサーチップ、センサー、及びペプチジルアルギニンデイミナーゼの活性評価方法

Also Published As

Publication number Publication date
WO2016205828A3 (en) 2017-02-02
EP3311176A4 (en) 2019-03-13
US11105817B2 (en) 2021-08-31
CN107923917A (zh) 2018-04-17
WO2016205828A2 (en) 2016-12-22
US20180299467A1 (en) 2018-10-18
EP3311176A2 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US11105817B2 (en) Role of citrullination in diagnosing diseases
Benjamin Larman et al. Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis
Taylor et al. An alternative strategy to determine the mitochondrial proteome using sucrose gradient fractionation and 1D PAGE on highly purified human heart mitochondria
JP6826543B2 (ja) アルツハイマー病に関係する生体分子
JP5775568B2 (ja) 診断方法
JP6469074B2 (ja) 放射線感受性を判定するための方法
Brioschi et al. Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors
KR20110020853A (ko) 유전자 또는 단백질 발현 프로파일을 이용한 신장 동종이식 거부반응 진단방법
JP5701994B2 (ja) シトルリン化タンパク質：生理学的および病理学的疾患のマーカーとしての心筋タンパク質の翻訳後修飾
Audano et al. Zc3h10 is a novel mitochondrial regulator
Birner et al. Proteomic profiling implies mitochondrial dysfunction in tachycardia-induced heart failure
US20170269103A1 (en) Assessment of Heart Failure and Arrhythmic Risk Stratification by Measuring Circulating Hu Proteins
Chang et al. Proteomic analyses and identification of arginine methylated proteins differentially recognized by autosera from anti-Sm positive SLE patients
Sato et al. Proteomic analysis of masticatory muscle tendon–aponeurosis hyperplasia: A preliminary study using a 2D-DIGE system
US20230144446A1 (en) Blood-based diagnostic assays for alzheimer's disease
HK40110041A (zh) 用於阿尔茨海默病的基於血液的诊断测定
Quero et al. Proteomics of toxic oil syndrome in humans: Phenotype distribution in a population of patients
Bathon et al. Citrullination of myofilament proteins in heart failure
Pandit Regulation of mitochondrial gene expression in multiple sclerosis cortex
Sjögren The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2-20 and peptides as sample quality indicators
Heaven Proteomic Analysis of Rosenthal Fibers and the Development of Software for Proteomics
WO2017046592A1 (en) Downstream targets of pink1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201102